Appeal No. 2006-1036 Application No. 10/191,760 any of the dogs . . . subsequent to treatment with the Hd-Ad vector.” Thus, the reduction in bleeding events provides evidence that a therapeutic effect was achieved. SUMMARY Because we found that the evidence of record as a whole supported the enablement of the claimed methods at the claimed dosages, we reverse the enablement rejection under 35 U.S.C. § 112, first paragraph. REVERSED DONALD E. ADAMS ) Administrative Patent Jude ) ) ) ) BOARD OF PATENT LORA M. GREEN ) Administrative Patent Judge ) APPEALS AND ) ) INTERFERENCES ) RICHARD M. LEBOVITZ ) Administrative Patent Judge ) LMG/jlb 9Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: September 9, 2013